8-K: Aprea Therapeutics Holds 2024 Annual Meeting, Elects Directors and Ratifies Auditor

Aprea Therapeutics held its 2024 annual meeting, electing three Class II directors and ratifying its independent auditor.

Summary

• Aprea Therapeutics held its 2024 annual meeting of stockholders on June 20, 2024.
• Approximately 70.46% of the company's shares were represented at the meeting, constituting a quorum.
• Stockholders elected Michael Grissinger, Gabriela Gruia, M.D., and Rifat Pamukcu, M.D. as Class II directors, each to serve until the 2027 annual meeting.
• The appointment of EisnerAmper LLP as the company's independent registered public accounting firm for the 2024 fiscal year was ratified.

Sentiment

Score: 7

Explanation: The document reflects standard corporate governance procedures, indicating a stable and routine operational environment. There are no indications of significant positive or negative events.

Positives

• The company successfully held its annual meeting with a strong representation of shares.
• The election of directors and ratification of the auditor were approved by the stockholders.

Management Comments

• Oren Gilad, Ph.D., President and Chief Executive Officer, signed the report on behalf of Aprea Therapeutics, Inc.

Industry Context

This is a standard corporate governance event for a publicly traded company, ensuring compliance with regulatory requirements and shareholder representation.

Comparison to Industry Standards

• The election of directors and ratification of auditors are standard practices for publicly traded companies like Aprea Therapeutics.
• The level of shareholder representation at 70.46% is within the expected range for such meetings.

Stakeholder Impact

• Shareholders have exercised their voting rights to elect directors and ratify the auditor.
• The company has fulfilled its corporate governance obligations.

Key Dates

Keywords

Annual Meeting, Directors, EisnerAmper LLP, Auditor, Stockholders, Corporate Governance